Geisinger and Eisai to test real-world validity of AI-powered Passive Digital Marker (PDM) in detecting early cognitive impairment and dementia

By SharpBrains | April 12, 2022

Research col­lab­o­ra­tion will test nov­el algorithm’s effec­tive­ness on Geisinger data (press release): Geisinger and Eisai Inc. today announced a col­lab­o­ra­tive effort to study the poten­tial effec­tive­ness of an arti­fi­cial intel­li­gence (AI) tool in the detec­tion of cog­ni­tive impair­ment that could iden­ti­fy demen­tias, includ­ing Alzheimer’s dis­ease (AD). If effec­tive, the AI tool could poten­tial­ly be developed…

Read More

First, do no harm? Study finds association between androgen deprivation therapy and increased risk of Alzheimer’s disease

By SharpBrains | December 15, 2015

Pros­trate Can­cer Treat­ment Tied To Alzheimer’s Risk (New York Times): “Hor­mone ther­a­py, a com­mon treat­ment for prostate can­cer, is asso­ci­at­ed with an increased risk for Alzheimer’s dis­ease, a new study has found…Overall, those treat­ed with hor­mone ther­a­py had an 88 per­cent increased risk of Alzheimer’s com­pared with oth­er patients. The longer 

Read More